Biopharmaceutical company MediWound agreed last week to a deal giving Avalon Pharmaceutical S.A. the rights to market and distribute its severe burn treatment product NexoBrid is several Latin American countries.
Under the agreement, Avalon will work with MediWound to provide individuals in Chile, Colombia, Ecuador Panama and Peru access to the topically applied product that is used to treat severe burns. NexoBrid removes dead or damaged tissue, called eschar, without causing harm to the surrounding healthy tissues. While current topical treatments tend to take a long time to work, NexoBrid has proven to be able to remove eschar within four hours.
“We are pleased to announce our third distribution agreement in Latin America and look forward to working with Avalon to expand access to NexoBrid for burn victims across many additional countries in the region,” MediWound President and CEO Gal Cohen said. “We are executing our global marketing strategy as planned and continue to seek opportunities to further expand our collaborations. We have distribution partners in most of South America and will now focus our efforts towards Brazil as well as on the major Asia Pacific countries with the goal of making NexoBrid more broadly accessible to burn victims worldwide while growing NexoBrid sales and creating value for our stakeholders.”
NexoBrid has been commercially launched in Europe and Israel.
